Oberland Capital

Biohaven Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for neurological diseases and other therapeutic areas. The company focuses on life-changing therapies targeting conditions such as neuromuscular disorders, metabolic diseases, obsessive-compulsive disorder, and various forms of cancer. Its diverse pipeline includes late-stage product candidates that utilize mechanisms such as calcitonin gene-related peptide receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors. Notable candidates in its pipeline include BHV3000-301, BHV3000-302, and BHV3000-303, among others. Biohaven's commitment to addressing unmet medical needs positions it as a significant player in the biopharmaceutical landscape.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

ImmunityBio, founded in 2014, specializes in developing immunotherapies to combat various cancers without relying on high-dose chemotherapy. Its portfolio includes an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), and other therapies targeting tumor-associated antigens and neoepitopes.

ImmunityBio, founded in 2014, specializes in developing immunotherapies to combat various cancers without relying on high-dose chemotherapy. Its portfolio includes an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), and other therapies targeting tumor-associated antigens and neoepitopes.

Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines. The company has a growing proprietary pipeline that includes several clinical candidates such as glepaglutide for short bowel syndrome and dasiglucagon for diabetes management and congenital hyperinsulinism. Zealand's first developed medicine, lixisenatide, is a once-daily GLP-1 analogue for Type 2 diabetes, marketed globally outside the US. The company has established collaborations with major pharmaceutical partners, including Sanofi, Helsinn Healthcare, and Boehringer Ingelheim, enhancing its product offerings and expanding its reach in the market. Zealand Pharma is committed to advancing innovative therapies, with multiple projects in various stages of clinical development and preclinical research.

Centessa Pharmaceuticals is a biopharmaceutical company that focuses on advancing validated drug programs through an asset-centric R&D model. Each program is developed by dedicated subsidiaries, supported by centralized infrastructure and expert management.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for debilitating liver diseases. Its primary focus is on Maralixibat, an investigational oral drug in Phase 3 trials for treating progressive familial intrahepatic cholestasis disease and Alagille syndrome.

Primmune Therapeutics is a biotechnology company developing orally administered small molecule toll-like receptor 7 (TLR7) agonists to stimulate innate immunity in cancer immunotherapy. The TLR7 agonists aim to activate systemic innate immune responses, promoting cytokine and chemokine production, NK cell activation, and B-cell proliferation to support anti-tumor activity. The company intends to combine these agents with adaptive cancer therapies such as checkpoint inhibitors to improve response rates and durability, and targets metastatic cancers.

NorthStar Medical Radioisotopes, LLC, founded in 2006 and based in Madison, Wisconsin, specializes in developing technologies and raw materials for the nuclear medicine market in the United States. As a subsidiary of NorthStar Medical Technologies, the company addresses critical supply challenges in the production of medical isotopes, particularly Molybdenum-99 and Technetium-99m, which are essential for diagnostic imaging in various medical fields, including neurology, oncology, and cardiology. NorthStar also produces therapeutic isotopes such as Actinium-225 and Bismuth-213 for treating incurable diseases like cancer and HIV. The company’s innovative RadioGenix System enables the production of Tc-99m from non-uranium based molybdenum-99, providing a reliable and efficient alternative to traditional methods. NorthStar Medical Radioisotopes is committed to enhancing patient care and advancing clinical research through its patented technologies and high-quality radioisotope products.

Impact Biomedicines, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative treatments for patients with myeloproliferative neoplasms and other cancers. Founded in 2016 and headquartered in San Diego, California, the company is primarily centered on its lead product, fedratinib, a potent and selective oral small molecule JAK2 kinase inhibitor. Fedratinib is being developed for the treatment of myelofibrosis and polycythemia vera, with additional potential applications in acute myeloid leukemia and colorectal cancer. As of February 2018, Impact Biomedicines operates as a subsidiary of Bristol-Myers Squibb Company.

Melinta Therapeutics is a pharmaceutical company dedicated to discovering, developing, and commercializing novel antibiotics to combat drug-resistant infections. Its portfolio includes Baxdela, Vabomere, Orbactiv, and Minocin, treating various bacterial infectious diseases. The company's mission is driven by the urgent need for new therapies against antibiotic-resistant pathogens.

ClearPoint Neuro is a medical device company specializing in platforms for minimally invasive surgical procedures in the brain and heart under direct magnetic resonance imaging (MRI) guidance. Its flagship product, the ClearPoint system, enables precise insertion of catheters, electrodes, and laser fibers for treating neurological conditions and performing biopsies.

ClearPoint Neuro is a medical device company specializing in platforms for minimally invasive surgical procedures in the brain and heart under direct magnetic resonance imaging (MRI) guidance. Its flagship product, the ClearPoint system, enables precise insertion of catheters, electrodes, and laser fibers for treating neurological conditions and performing biopsies.